Weight Gain: A Possible Side Effect of All Antiretrovirals

Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through the SCOLTA cohort revealed significant 1-year BMI increase in patients treated with dolutegravir (P = .004), raltegravir (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Taramasso, Lucia, Ricci, Elena, Menzaghi, Barbara, Orofino, Giancarlo, Passerini, Simone, Madeddu, Giordano, Martinelli, Canio Vito, De Socio, Giuseppe Vittorio, Squillace, Nicola, Rusconi, Stefano, Bonfanti, Paolo, Di Biagio, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727459/
https://www.ncbi.nlm.nih.gov/pubmed/29255735
http://dx.doi.org/10.1093/ofid/ofx239
Descripción
Sumario:Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through the SCOLTA cohort revealed significant 1-year BMI increase in patients treated with dolutegravir (P = .004), raltegravir (P = .0004), elvitegravir (P = .004), darunavir (P = .0006), and rilpivirine (P = .029). BMI gain correlated with low baseline BMI (P = .002) and older age (P = .0007) in Centers for Disease Control and Prevention stages A/B, with lower BMI (P = .005) and CD4+ T-cell count (P = .007) at enrollment in stage C.

Ejemplares similares